Beximco Pharmaceuticals (LON:BXP) Share Price Passes Below Two Hundred Day Moving Average of $35.76

Shares of Beximco Pharmaceuticals Limited (LON:BXP – Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 35.76 ($0.48) and traded as low as GBX 24 ($0.32). Beximco Pharmaceuticals shares last traded at GBX 25.60 ($0.34), with a volume of 63,764 shares [...]

featured-image

Shares of Beximco Pharmaceuticals Limited ( LON:BXP – Get Free Report ) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 35.76 ($0.

48) and traded as low as GBX 24 ($0.32). Beximco Pharmaceuticals shares last traded at GBX 25.



60 ($0.34), with a volume of 63,764 shares trading hands. Beximco Pharmaceuticals Stock Up 6.

7 % The stock has a 50-day moving average of GBX 30.70 and a 200-day moving average of GBX 35.76.

The company has a debt-to-equity ratio of 14.73, a current ratio of 1.80 and a quick ratio of 0.

37. The firm has a market cap of £114.20 million, a price-to-earnings ratio of 365.

71 and a beta of 0.64. Beximco Pharmaceuticals Company Profile ( Get Free Report ) Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh.

The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. See Also Receive News & Ratings for Beximco Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beximco Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .

.